Short-Course Regimens of Artesunate-Fosmidomycin in Treatment of Uncomplicated <i>Plasmodium falciparum</i> Malaria
Steffen Borrmann(Heidelberg University), Peter G. Kremsner(Centre de Recherche Médicales de Lambaréné), David K. Hutchinson(Australian Antarctic Division), Gilbert Esser(Albert Schweitzer Hospital), Félicien Moussavou(Albert Schweitzer Hospital), Jochen Wiesner, Sunny Oyakhirome(Albert Schweitzer Hospital), Pierre‐Blaise Matsiegui(Albert Schweitzer Hospital), Ayôla Akim Adégnika(Fondation pour la Recherche Stratégique), Maryvonne Kombila(Université des Sciences de la Santé), Saadou Issifou(Albert Schweitzer Hospital), Ingrid Lundgren(St. Luke's Children's Hospital), Hassan Jomaa, Michael Ramharter(Universität Hamburg)
Cited by 74
Related Papers
A Worldwide Map of<i>Plasmodium falciparum</i>K13-Propeller Polymorphisms
|New England Journal of Medicine|2016|574
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine
|New England Journal of Medicine|2015|451
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
|Nature Communications|2021|295
The Eocene–Oligocene transition: a review of marine and terrestrial proxy data, models and model–data comparisons
|Climate of the past|2021|275
Fosmidomycin, a Novel Chemotherapeutic Agent for Malaria
|Antimicrobial Agents and Chemotherapy|2003|214